Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 4Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 5Carcinoma, Transitional Cell 4Ureteral Neoplasms 2Urologic Neoplasms 1Urethral Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1Metastatic Urothelial Cancer 1

Interventions

Gemcitabine 9Cisplatin 5vinflunine 4Carboplatin 4pembrolizumab 2enfortumab vedotin 2Ramucirumab 2Platinum 2Docetaxel 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1genexol-PM 1eribulin 1enzalutamide 1dehydroftorafur 1carotuximab 1avelumab 1atezolizumab 1abexinostat 1Vitamin D 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide 1Molecular Diagnostic Techniques 1Mitozytrex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Ureteral Neoplasms × enfortumab vedotin × Clear all
NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03219333 2024-08-27

EV-201

Astellas Pharma Inc

Phase 2 Completed
219 enrolled 32 charts 2 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡